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Summary
The analysis of cancer genomic data has long suffered “the curse of dimensionality”. Sample sizes
for most cancer genomic studies are a few hundreds at most while there are tens of thousands of
genomic features studied. Various methods have been proposed to leverage prior biological knowl-
edge, such as pathways, to more effectively analyze cancer genomic data. Most of the methods
focus on testing marginal significance of the associations between pathways and clinical phe-
notypes. They can identify relevant pathways, but do not involve predictive modeling. In this
article, we propose a Pathway-based Kernel Boosting (PKB) method for integrating gene path-
way information for sample classification, where we use kernel functions calculated from each
pathway as base learners and learn the weights through iterative optimization of the classifica-
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tion loss function. We apply PKB and several competing methods to three cancer studies with
pathological and clinical information, including tumor grade, stage, tumor sites, and metastasis
status. Our results show that PKB outperforms other methods, and identifies pathways relevant
to the outcome variables.
Key words: Classification, Gene set enrichment analysis, Boosting, Kernel method
1. Introduction
High-throughput genomic technologies have enabled cancer researchers to study the associations
between genes and clinical phenotypes of interest. A large number of cancer genomic data sets
have been collected with both genomic and clinical information from the patients. The analyses
of these data have yielded valuable insights on cancer mechanisms, subtypes, prognosis, and
treatment response.
Although many methods have been developed to identify genes informative of clinical pheno-
types and build prediction models from these data, it is often difficult to interpret the results with
single-gene focused approaches, as one gene is often involved in multiple biological processes, and
the results are not robust when the signals from individual genes are weak. As a result, pathway-
based methods have gained much popularity (e.g. Subramanian and others (2005)). A pathway
can be considered as a set of genes that are involved in the same biological process or molecular
function. It has been shown that gene-gene interactions may have stronger effects on phenotypes
when the genes belong to the same pathways or regulatory networks (Carlson and others, 2004).
There are many pathway databases available, such as the Kyoto Encyclopedia of Genes and
Genomes (Kanehisa and Goto, 2000), the Pathway Interaction Database (Schaefer and others,
2008), and Biocarta (Nishimura, 2001). By utilizing pathway information, researchers may ag-
gregate weak signals from the same pathway to identify relevant pathways with better power
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and interpretability. Many pathway-based methods, such as GSEA (Subramanian and others,
2005), LSKM (Liu and others, 2007), and SKAT (Wu and others, 2011), focus on testing the
significance of pathways. These methods consider each pathway separately and evaluate statis-
tical significance for its relevance to the phenotype. In other words, these methods study each
pathway separately without considering the effects of other pathways.
Given that many pathways likely contribute to the onset and progression of a disease, it is of
interest to study the contribution of a specific pathway to phenotypes conditional on the effects
of other pathways. This is usually achieved by regression models. Wei and Li (2007) and Luan
and Li (2007) proposed two similar models, Nonparametric Pathway-based Regression (NPR)
and Group Additive Regression (GAR). Both models employ a boosting framework, construct
base learners from individual pathways, and perform prediction through additive models. Due
to the additivity at the pathway level, these models only considered interactions among genes
within the same pathway, but not across pathways. Since our proposed method is motivated by
the above two models, more details of these methods will be described in Section 2. In genomics
data analysis, multiple kernel methods (Go¨nen and Margolin, 2014; Aiolli and Donini, 2015)
are also commonly used when predictors have group structures. In these methods, one kernel is
assigned to each pathway and a meta-kernel is computed as a weighted sum of the individual
kernels. The kernel weights are estimated through optimization, and can be considered as a
measure of pathway importance. Although multiple kernel methods are not designed specifically
for integrating pathway information, they have been successful in genomic data analysis (Costello
and others, 2014).
In this paper, we propose a Pathway-based Kernel Boosting (PKB) method for sample classi-
fication. In our boosting framework, we use the second order approximation of the loss function
instead of the first order approximation used in the usual gradient descent boosting method,
which allows for deeper descent at each step. We introduce two types of regularizations (L1 and
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L2) for selection of base learners in each iteration, and propose algorithms for solving the regular-
ized problems. In Section 3, we conduct simulation studies to evaluate the performance of PKB,
along with four other competing methods. In Section 4, we apply PKB to three cancer genomic
data sets, where we use gene expression data to predict several patient phenotypes, including
tumor grade, stage, tumor site, and metastasis status.
2. Methods
Suppose our observed data is collected from N subjects. For subject i, we use a p dimensional
vector xi = (xi1, xi2, . . . , xip) to denote the normalized gene expression profile, and yi ∈ {1,−1}
to denote its class label. Similarly, the gene expression levels of a given pathway m with pm genes
can be represented by x
(m)
i = (x
(m)
i1 ,x
(m)
i2 , . . . ,x
(m)
ipm
), which is a sub-vector of xi.
The log loss function is commonly used in binary classifications with the following form:
l(y, F (x)) = log(1 + e−yF (x)),
and is minimized by
F ∗(x) = log
p(y = 1|x)
p(y = −1|x) ,
which is exactly the log odds function. Thus the sign of an estimated F (x) can be used to classify
sample x as 1 or -1. Since genes within the same pathway likely have much stronger interactions
than genes in different pathways, in our pathway-based model setting, we assume additive effects
across pathways, and focus on capturing gene interactions within pathways:
F (x) =
M∑
m=1
Hm(x
(m)),
where each Hm is a nonlinear function that only depends on expressions of genes in the mth
pathway, and summarizes its contribution to the log odds function. Due to the additive nature
of this model, it only captures gene interactions within each pathway, but not across pathways.
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Two existing methods, NPR (Wei and Li, 2007) and GAR (Luan and Li, 2007), employed the
Gradient Descent Boosting (GDB) framework (Friedman, 2001) to estimate the functional form
of F (x) nonparametrically. GDB can be considered as a functional gradient descent algorithm to
minimize the empirical loss function, where in each descent iteration, an increment function that
best aligns with the negative gradient of the loss function (evaluated at each sample point) is
selected from a space of base learners and then added to the target function F (x). NPR and GAR
extended GDB to be pathway-based by applying the descent step to each pathway separately, and
selecting the base learner from the pathway that provides the best fit to the negative gradient.
NPR and GAR differ in how they construct base learners from each pathway: NPR uses
regression trees, and GAR uses linear models. Due to the linearity assumption of GAR, it lacks
the ability to capture complex interactions among genes in the same pathways. Using regression
tree as base learners enables NPR to model interactions, however, there is no regularization in
the gradient descent step, which can lead to selection bias that prefers large pathways.
Motivated by NPR and GAR, we propose the PKB model, where we employ kernel functions
as base learners, optimize loss function with second order approximation (Friedman and others,
2000) which gives Newton-like descent speed, and also incorporates regularization in selection of
pathways in each boosting iteration.
2.1 PKB model
Kernel methods have been applied to a variety of statistical problems, including classification
(Guyon and others, 2002), regression (Drucker and others, 1997), dimension reduction (Fuku-
mizu and others, 2009), and others. Results from theories of Reproducing Kernel Hilbert Space
(Friedman and others, 2001) have shown that kernel functions can capture complex interactions
among features. For pathway m, we construct a kernel-based function space as the space for base
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learners
Gm = {g(x) =
N∑
i=1
Km(x
(m)
i ,x
(m))βi + c : β1, β2, . . . , βN , c ∈ R},
where Km(·, ·) is a kernel function that defines similarity between two samples only using genes
in the mth pathway. The overall base learner space is the union of the spaces constructed from
each pathway alone: G = ∪Mm=1Gm.
Estimation of the target function F (x) is obtained through iterative minimization of the
empirical loss function evaluated at the observed data. The empirical loss is defined as
L(y,F) =
1
N
N∑
i=1
l(yi, F (xi)),
where F = (F (x1), F (x2), . . . , F (xN )). In the rest of this article, we will use bold font of a
function to represent the vector of the function evaluated at the observed xi’s. Assume that at
iteration t, the estimated target function is Ft(x). In the next iteration, we aim to find the best
increment function f ∈ G, and add it to Ft(x). Expanding the empirical loss at Ft to the second
order, we can get the following approximation
Lapprox(y,Ft + f) = L(y,Ft) +
1
N
N∑
i=1
[ht,if(xi) +
1
2
qt,if(xi)
2], (2.1)
where
ht,i =
∂L(y,Ft)
∂Ft(xi)
= − yi
1 + eyiFt(xi)
,
qt,i =
∂2L(y,Ft)
∂Ft(xi)2
=
eyiFt(xi)
(1 + eyiFt(xi))2
are the first order and second order derivatives with respect to each Ft(xi), respectively. We
propose a regularized loss function that incorporates both the approximated loss and a penalty
on the complexity of f :
LR(f) = Lapprox(y,Ft + f) + Ω(f) (2.2)
=
1
N
N∑
i=1
qi,t
2
(
hi,t
qi,t
+ f(xi))
2 + Ω(f) + C(y,Ft), (2.3)
PKB: Pathway-based Kernel Boosting 7
Table 1. An overview of the PKB algorithm
1. Initialize target function as an optimal constant:
F0(x) = arg min
r∈R
1
n
N∑
i=1
l(yi, r)
For t from 0 to T-1 (maximum number of iterations) do:
2. calculate first and second derivatives:
ht,i = − yi
1 + eyiFt(xi)
, qt,i =
eyiFt(xi)
(1 + eyiFt(xi))2
3. optimize the regularized loss function in the base learner space:
fˆ = arg min
f∈G
LR(f)
4. find the step length with the steepest descent:
dˆ = arg min
d∈R+
L(y,Ft + dfˆ)
5. update the target function:
Ft+1(x) = Ft(x) + νdˆfˆ(x)
End For
return FT (x)
where Ω(·) is the penalty function. Since f ∈ G is a linear combination of kernel functions
calculated from a specific pathway, the norm of the combination coefficients can be used to define
Ω(·). We consider both L1 and L2 norm penalties, and solutions regarding each penalty option
are presented in sections 2.1.1 and 2.1.2, respectively. C(y,Ft) is a constant term with respect
to f . Therefore, we only use the first two terms of equation (2.3) as the working loss function in
our algorithms. We will also drop C(y,Ft) in the expression of LR(f) in the following sections
for brevity. Such a penalized boosting step has been employed in several methods (e.g. Johnson
and Zhang (2014)). Intuitively, the regularized loss function would prefer simple solutions that
also fit the observed data well, which usually leads to more robust models.
We then optimize the regularized loss for the best increment direction
fˆ = arg min
f∈G
LR(f).
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Given the direction, we find the deepest descent step length by minimizing over the original loss
function
dˆ = arg min
d∈R+
L(y,Ft + dˆfˆ),
and update the target function to Ft+1(x) = Ft(x) + νdˆfˆ , where ν is a learning rate parame-
ter. The above fitting procedure is repeated until a certain pre-specified number of iterations is
reached. A complete procedure of the PKB algorithm is illustrated in Table 1.
2.1.1 L1 penalized boosting
The core step of PKB is the optimization of the regularized loss function (see step 3 of Table
1). Note that G is the union of the pathway-based learner spaces, thus
fˆ = arg min
G
LR(f)
= arg min
fˆm
{LR(fˆm) : fˆm = arg min
f∈Gm
LR(f),m = 1, 2, . . . ,M}.
To solve for fˆ , it is sufficient that we obtain the optimal fˆm in each pathway-based subspace. Due
to the way we construct the subspaces, in a given pathway m, f takes a parametric form as linear
combination of the corresponding kernel functions. This helps us further reduce the optimization
problem to
min
f∈Gm
LR(f) = min
β,c
1
N
N∑
i=1
qi,t
2
(
hi,t
qi,t
+KTm,iβ + c)
2 + Ω(f) (2.4)
= min
β,c
1
N
(ηt +Kmβ + 1Nc)
TWt(ηt +Kmβ + 1Nc) + Ω(f), (2.5)
where
ηt = (
h1,t
q1,t
,
h2,t
q2,t
, . . . ,
hN,t
qN,t
)T ,
Wt = diag(
q1,t
2
,
q2,t
2
, . . . ,
qN,t
2
),
Km =
[
Km(x
(m)
i ,x
(m)
j )
]
i,j=1,2,...,N
.
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Km,i is the ith column of kernel matrix Km, and 1N is an N by 1 vector of 1’s. We use the L1
norm Ω(f) = λ‖β‖1, as the penalty term, where λ is a tuning parameter adjusting the amount
of penalty we impose on model complexity. We also prove that after certain transformations, the
optimization can be converted to a LASSO problem without intercept
min
β
1
N
‖η˜ + K˜mβ‖22 + λ‖β‖1, (2.6)
where
η˜ = W
1
2
t
[
IN − 1N1
T
NWt
tr(Wt)
]
ηt
K˜m = W
1
2
t
[
IN − 1N1
T
NWt
tr(Wt)
]
Km.
Therefore, β can be efficiently estimated using existing LASSO solvers. The proof of the equiva-
lence between the two problems is provided in Section S1 of the supplementary materials.
2.1.2 L2 penalized boosting
In the L2 penalized boosting, we replace Ω(f) in the objective function of (2.5) with λ‖β‖22.
Following the same transformation as in section 2.1.1, the objective can also be converted to a
standard Ridge Regression (see S1 of supplementary material)
min
β
1
N
‖η˜ + K˜mβ‖22 + λ‖β‖22, (2.7)
which allows closed form solution
βˆ = −(K˜TmK˜m +NλIN )−1K˜Tmη˜.
Both the L1 and L2 boosting algorithms require the specification of the penalty parameter
λ, which controls step length (the norm of fitted β) in each iteration, and additionally controls
solution sparsity in the L1 case. Feasible choices of λ might be different for different scenarios,
depending on the input data and also the choice of the kernel. Either too small or too large λ
10 L. Zeng and others
values would lead to big leaps or slow descent speed. Under the L1 penalty, poor choices of λ
can even result in all-zero β, which makes no change to the target function. Therefore, we also
incorporate an optional automated procedure to choose the value of λ in PKB. Computational
details of the procedure are provided in Section S2 of the supplementary materials. We recommend
the use of the automated procedure to calculate a feasible λ, and try a range of values around it
(e.g. the calculated value multiplies 1/25, 1/5, 1, 5, 25) for improved performance.
Lastly, the final target function at iteration T can be written as
FT (x) =
M∑
m=1
N∑
i=1
Km(x
(m)
i ,x
(m))β
(m)
i + C,
where β(m) = (β
(m)
1 , β
(m)
2 , . . . , β
(m)
N ) are the combination coefficients of kernel functions from
pathway m. We use ‖β(m)‖2 as a measure of importance (or weight) in the target function. It
is obvious that only the pathways that are selected at least once in the boosting procedure will
have non-zero weights. Because FT (x) is an estimation of the log odds function, sign[FT (x)] is
used as the classification rule to assign x to 1 or -1.
3. Simulation studies
We use simulation studies to assess the performance of PKB. We consider the following three
underlying truth models:
- Model 1:
F (x) = 2x
(1)
1 + 3x
(1)
2 + exp(0.8x
(2)
1 + 0.8x
(2)
2 ) + 4x
(3)
1 x
(3)
2
- Model 2:
F (x) = 4 sin(x
(1)
1 + x
(1)
2 ) + 3|x(2)1 − x(2)2 |+ 2x(3)1
2 − 2x(3)2
2
- Model 3:
F (x) = 2
10∑
m=1
‖x(m)‖2
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where F (x) is the true log odds function, and x
(m)
i represents the expression level of the ith gene
in the mth pathway. We include different functional forms of pathway effects in F (x), including
linear, exponential, polynomial and others. In models 1 and 2, only two genes in each of the
first three pathways are informative to sample classes; in model 3, only genes in the first ten
pathways are informative. We generated a total of six datasets, two for each model, with different
numbers of irrelevant pathways (M= 50 and 150) corresponding to different noise levels. We set
the size of pathways to 5 and sample size to 900 in all simulations. Gene expression data (xi’s)
were generated following standard normal distribution. We then calculated the log odds F (xi)
for each sample, and use the median-centered F (xi) values to generate corresponding binary
outcomes yi ∈ {−1, 1}∗.
We divided the generated datasets into three folds, and each time used two folds as training
data and the other fold as testing data. The number of maximum iterations T is important to
PKB, as using a large T will likely induce overfitting on training data and poor prediction on
testing data. Therefore, we used an additional layer of cross validation within the training data
to select T . We further divided the training data into three folds, and each time trained the PKB
model using two folds while monitoring the loss function on the other fold at every iteration.
Eventually, we identified the iteration number T ∗ with the minimum averaged loss, and applied
PKB to the whole training dataset up to T ∗ iterations.
We first evaluated the ability of PKB to correctly identify relevant pathways. For each simu-
lation scenario, we calculated the average optimal weights across different cross validation runs,
and the results are shown in Figure 1, where the X-axis represents different pathways, and the
length of bars above them represents corresponding weights in the prediction functions. Note
that for the underlying Model 1 and Model 2, only the first three pathways were relevant to the
outcome, and in Model 3, the first ten pathways were relevant. In all the cases, PKB successfully
∗We use the median-centered F (xi) values to generate outcome, so that the proportions of 1’s and -1’s are
approximately 50%.
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Fig. 1. Estimated pathway weights by PKB in simulation studies. The X-axis represents pathways, and
the Y-axis represents estimated weights. Based on the simulation settings, the first three pathways are
relevant in Models 1 and 2, and the first ten pathways are relevant in Model 3. M represents the number
of simulated pathways.
assigned the largest weights to relevant pathways. Since PKB is an iterative approach, at some
iterations, certain pathways irrelevant to the outcome may be selected by chance and added to
the prediction function. This explains the non-zero weights of the irrelevant pathways, and their
values are clearly smaller than those of relevant pathways.
We also applied several commonly used methods to the simulated datasets, and compared
their prediction accuracy with PKB. These methods included both non-pathway-based meth-
ods: Random Forest (Breiman, 2001) and SVM (Guyon and others, 2002), and pathway-based
methods: NPR (Wei and Li, 2007) and EasyMKL (Aiolli and Donini, 2015). We used the same
three-fold split of the data, as we used when applying PKB, to perform cross-validations for
each competing method. The average prediction performance of the methods is summarized in
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Table 2. It can be seen that the pathway-based methods generally performed better than the
non-pathway-based methods in all simulated scenarios. Among the pathway-based methods, the
one that utilized kernels (EasyMKL) had comparable performances with the tree-based NPR
method in Models 1 and 2, but had clearly superior performance in Model 3. This was likely
due to the functional form of the log odds function F (x) of Model 3. Note that genes in relevant
pathways were involved in F (x) in terms of their L2 norms, which is hard to approximate by
regression tree functions, but can be well captured using kernel methods. In all scenarios, the best
performance was achieved by one of the PKB methods. In four out of six scenarios, the PKB-L2
method produced the smallest prediction errors, while in the other two scenarios, PKB-L1 was
slightly better. Although PKB-L1 and PKB-L2 had similar performances, PKB-L1 was usually
computationally faster, because in the optimization step of each iteration, the L1 algorithm only
looked for sparse solution of β’s, which can be done more efficiently than PKB-L2, which involves
matrix inverse.
Method
Model 1 Model 2 Model 3
50 150 50 150 50 150
PKB-L1 0.151 0.196 0.198 0.189 0.179 0.21
PKB-L2 0.158 0.185 0.201 0.183 0.157 0.173
Random Forest 0.305 0.331 0.290 0.328 0.341 0.400
SVM 0.353 0.431 0.412 0.476 0.431 0.492
NPR 0.271 0.321 0.299 0.317 0.479 0.440
EasyMKL 0.253 0.284 0.268 0.330 0.212 0.300
Table 2. Classification error rate from PKB and competing methods in simulation studies. The numbers
below each model represent the number of pathways simulated in the data sets.
4. Real data applications
We applied PKB to gene expression profiles to predict clinical features in three cancer studies,
including breast cancer, melanoma, and glioma. The clinical variables we considered included
tumor grade, tumor site, and metastasis status, which were all of great importance to cancer.
14 L. Zeng and others
We used three commonly used pathway databases: KEGG, Biocarta, and Gene Ontology
(GO) Biological Process pathways. These databases provide lists of pathways with emphasis
on different biological aspects, including molecular interactions and involvement in biological
processes. The number of pathways from these databases ranges from 200 to 4,000. There is
considerable overlap between pathways. To eliminate redundant information and control the
overlap between pathways, we applied a preprocessing step to the databases with details provided
in the supplementary material Section S4.2.
Similar to the simulation studies, we compared the performances from different methods based
on three fold cross validations following the same procedure as elaborated in Section 3. Most of
the methods we considered have tuning parameters. We searched through different parameter
configurations, and reported the best result from cross-validation for each method. More details
of the data sets and the implementations can be found in the supplementary material Section
S4. Table 3 shows the classification error rates from all methods. The numbers in bold are the
optimal error rates for each column separately. In four out of five classifications, PKB was the best
method (usually with the L1 and L2 methods being the top two). In the other case (melanoma,
stage), NPR yielded the best results, with the PKB methods still ranking second and third.
We provide more detailed introductions to the data sets and clinical variables, and interpre-
tations of results by PKB in the following. For brevity of the article, we focus on presenting
results for three outcomes, one from each data set, and leave the other two in the supplementary
materials (Section S4.4).
4.1 Breast Cancer
Metabric is a breast cancer study that involved more than 2,000 patients with primary breast tu-
mors (Pereira and others, 2016). The data set provides copy number aberration, gene expression,
mutation, and long-term clinical follow-up information. We are interested in the clinical variable
PKB: Pathway-based Kernel Boosting 15
Method
Data sets
Metabric
(grade)
Glioma
(grade)
Glioma
(site)
Melanoma
(stage)
Melanoma
(met)
PKB-L1 0.274 0.283 0.168 0.304 0.081
PKB-L2 0.304 0.283 0.154 0.307 0.083
Random Forest 0.306 0.302 0.306 0.320 0.136
SVM 0.285 0.292 0.185 0.314 0.083
NPR 0.306 0.298 0.197 0.282 0.110
EasyMKL 0.297 0.302 0.291 0.314 0.100
Table 3. Classification error rates on real data. The names in the parenthesis of each data set are the
variables used as classification outcome. The best error rates are highlighted with bold font for each
column.
of tumor grade, which measures the abnormality of the tumor cells compared to normal cells
under a microscope. It takes a value of 1, 2, or 3. Higher grade indicates more abnormality and
higher risk of rapid tumor proliferation. Since grade 1 contained the fewest samples, we pooled
it together with grade 2 as one class, and treated grade 3 as the other class.
We then applied PKB to samples in subtype Lum B, where the sample sizes for the two classes
were most balanced (259 Grade 3 patients; 211 Grade 1,2 patients). For input gene expression
data, we used the normalized mRNA expression (microarray) data for 24,368 genes provided in
the data set. The model using GO Biological Process pathways and radial basis function (rbf)
kernel yielded the best performance (error rate 27.4%). To obtain the pathways most relevant to
tumor grade, we calculated the average pathway weights from the cross validation, and sorted
them from highest to lowest. Top fifteen pathways with the highest weights are presented in the
first columns of Table 4.
Among all pathways, the cell aggregation and sequestering of metal ion are the top two path-
ways in terms of the estimated pathway weights. Previous research has shown that cell aggregation
contributes to the inhibition of cell death and anoikis-resistance, thereby promoting tumor cell
proliferation. Genes in the cell aggregation pathway include TGFB2, MAPK14, FGF4, and FGF6,
which play important roles in the regulation of cell differentiation and fate (Zhang and others,
2010). Moreover, the majority of genes in the sequestering of metal ion pathway encode calcium-
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binding proteins, which regulates calcium level and different cell signaling pathways relevant to
tumorigenesis and progression (Monteith and others, 2007). Among these genes, S100A8 and
S100A9 have been identified as novel diagnostic markers of human cancer (Hermani and others,
2005). The results suggest that PKB has identified pathways that are likely relevant to breast
cancer grade.
4.2 Lower Grade Glioma
Glioma is a type of cancer developed in the glial cells in brain. As glioma tumor grows, it
compresses normal brain tissue and can lead to disabling or fatal results. We applied our method
to a lower grade glioma data set from TCGA, where only grade 2 and 3 samples were collected∗
(TCGA and others, 2015). After removal of missing values, the numbers of patients in the cohort
with grades 2 and 3 tumors were 248 and 265, respectively. We used grade as the outcome
variable to be classified, and applied PKB with different parameter configurations. After cross
validation, PKB using the third order polynomial (poly3) kernel and the GO Biological Process
pathways yielded an error rate of 28.3%, which was the smallest among all methods. The top
fifteen pathways selected in the model are listed in the second column of Table 4.
The estimated pathway weights indicate that the cell adhesion pathway and the neuropeptide
signaling pathway have the strongest association with glioma grade. Genes in the cell adhesion
pathways generally govern the activities of cell adhesion molecules. Turning off the expression
of cell-cell adhesion molecules is one of the hallmarks of tumor cells, by which tumor cells can
inhibit antigrowth signals and promote proliferation. Previous studies have shown that deletion
of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) gene can contribute
to cancer progression (Leung and others, 2006). Cell Adhesion Molecule 1 (CADM1), CADM2,
CADM3, and CADM4, serve as tumor suppressors and can inhibit cancer cell proliferation and
∗Grade 4 glioma, also known as glioblastoma, is studied in a separate TCGA study.
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induce apoptosis. Neuropeptide signaling pathway has also been implicated in tumor growth
and progression. Neuropeptide Y is highly relevant to tumor cell proliferation and survival. Two
NPY receptors, Y2R and Y5R, are also members of the neuropeptide signaling pathway. They are
considered as important stimulatory mediators in tumor cell proliferation (Tilan and Kitlinska,
2016).
4.3 Melanoma
The next application of PKB is to a TCGA cutaneous melanoma dataset (TCGA and others,
2015). Melanoma is most often discovered after it has metastasized, and the skin melanoma site
is never found. Therefore, the majority of the samples are metastatic. In this data set, there are
369 metastatic samples and 103 primary samples. It is of great interest to study the genomic
differences between the two types, thus we applied PKB to this data using metastatic/primary
as the outcome variable. Using the Biocarta pathways and rbf kernel produced the smallest clas-
sification error rate (8.1%) among all methods. Fifteen pathways that PKB found most relevant
to the outcome are presented in the third column of Table 4.
Two complement pathways, lectin induced complement pathway and classical complement
pathway, came out from the PKB model as the most significant pathways. Proteins in com-
plement system participate in a variety of biological processes of metastasis, such as epithelial-
mesenchymal transition (EMT). EMT is an important process in the initiation stage of metas-
tasis, through which cells in primary tumor lose cell-cell adhesion and gain invasive properties.
Complement activation by tumor cells can recruit stromal cells to the tumor and induce EMT.
Furthermore, complement proteins can mediate the degradation of extracellular matrix, thereby
promoting tumor metastasis (Pio and others, 2014).
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Metabric (grade) Glioma (grade) Melanoma (met)
1 Cell aggregation Homophilic cell adhesion via
plasma membrane adhesion
molecules
Lectin induced complement
pathway
2 Sequestering of metal ion Neuropeptide signaling path-
way
Classical complement path-
way
3 Glutathione derivative
metabolic process
Multicellular organismal
macromolecule metabolic
process
Phospholipase c delta in
phospholipid associated cell
signaling
4 Antigen processing and pre-
sentation of exogenous pep-
tide antigen via mhc class i
Peripheral nervous system
neuron differentiation
Fc epsilon receptor i signal-
ing in mast cells
5 Sterol biosynthetic process Positive regulation of hair
cycle
Inhibition of matrix metallo-
proteinases
6 Pyrimidine containing com-
pound salvage
Peptide hormone processing Regulation of map kinase
pathways through dual
specificity phosphatases
7 Protein dephosphorylation Hyaluronan metabolic pro-
cess
Estrogen responsive protein
efp controls cell cycle and
breast tumors growth
8 Homophilic cell adhesion via
plasma membrane adhesion
molecules
Positive regulation of
synapse maturation
Chaperones modulate inter-
feron signaling pathway
9 Cyclooxygenase pathway Stabilization of membrane
potential
Il-10 anti-inflammatory sig-
naling pathway
10 Establishment of protein
localization to endoplasmic
reticulum
Lymphocyte chemotaxis Reversal of insulin resistance
by leptin
11 Negative regulation of de-
phosphorylation
Insulin secretion Bone remodeling
12 Xenophagy Positive regulation of os-
teoblast proliferation
Cycling of ran in nucleocyto-
plasmic transport
13 Attachment of spindle micro-
tubules to kinetochore
Negative regulation of de-
phosphorylation
Alternative complement
pathway
14 Fatty acyl coa metabolic pro-
cess
Trophoblast giant cell differ-
entiation
Cell cycle: g2/m checkpoint
15 Apical junction assembly Synaptonemal complex orga-
nization
Hop pathway in cardiac de-
velopment
Table 4. Top fifteen pathways with the largest weights fitted by PKB. In each column, pathways are sorted
in descending order from top to bottom. Pathways in the first two columns are from GO Biological Process
pathways, and the third column from Biocarta.
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5. Discussion
In this paper, we have introduced the PKB model as a method to perform classification analysis
of gene expression data, as well as identify pathways relevant to the clinical outcomes of interest.
PKB usually yields sparse models in terms of the number of pathways, which enhances inter-
pretability of the results. Moreover, the pathway weights as defined in section 2 can be used as
a measure of pathway importance, and provides guidance for further experimental verifications.
Two types of regularizations are introduced in the optimization step of PKB, in order to
select simple model with good fitting. The L1 method enjoys a computational advantage due
to the sparsity of its solution. In simulations and real data applications, both methods yielded
comparable prediction accuracy. It is worth mentioning that the second-order approximation
of the log loss function is also necessary for efficiency of PKB. The approximation yields an
expression that is quadratic in terms of coefficients β, which allows the problem to be converted
to LASSO or Ridge Regression after regularizations are added. If the original loss function were
used, solving β would be more time consuming.
There are several limitations of the current PKB approach. First of all, when constructing
base learners from pathways, we use fixed bandwidth parameters (inverse of the number of genes
in each pathway) in the kernel functions. Ideally, we would like the model to auto-determine the
parameters. However, the number of such parameters is equal to the number of pathways, which
is often too large to tune efficiently. Therefore, it remains a challenging task for future research.
Second, we currently only use pathway as a criterion to group genes, and within each pathway,
all genes are treated equally. It is conceivable that the genes interact with each other through
an underlying interaction network, and intuitively, genes in the hub should get more weights
compared to genes on the periphery. With the network information available, it is possible to
build more sensible kernel functions as base learners. Third, the pathway databases only cover a
subset of the input genes. Both KEGG and Biocarta only include a few thousands of genes, while
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the number of input genes is usually beyond 15,000. Large number of genes, with the potential
to provide additional prediction power, remain unused in the model. In our applications, we
tried pooling together all unused genes and consider them as a new pathway, but it did not
significantly improve the results. Although genes annotated with pathways are supposed to be
most informative, it is still worth looking for smarter ways of handling unannotated genes.
6. Software
Python code along with a complete instruction for usage of PKB is available from website:
https://github.com/zengliX/PKB.
7. Supplementary Material
Supplementary material and reproduction code are available online at https://github.com/zengliX/PKB.
Reproduction-related input data sets are available upon request from the corresponding author
(hongyu.zhao@yale.edu).
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